WHO consultation on CCHF therapeutics and vaccine evaluation

31 October 2019 - Geneva, Switzerland

Agenda

Organized by:

R&D Blueprint
Powering research to prevent epidemics

HEALTH EMERGENCIES programme
## AGENDA

**Thursday 31 October**

*World Health Organization, Salle C  
Avenue Appia 20, Geneva, Switzerland*

**Chair – R. Brookmeyer**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Proposed speaker</th>
</tr>
</thead>
</table>
| 10:30 –    | **Opening remarks**  
Introduction, Objectives of the consultation (10 min)                | WHO                                       |
| 10:45      | **Part I Epidemiology and clinical manifestations of CCHF**           |                                           |
| 10:30 –    | What do we know (or don’t know) about CCHF epidemiology that is critical for planning clinical trials? (10 mins)  
Questions for clarifications (5 min)                                           | A. Mirazimi                               |
| 12:45      | What do we know (or don’t know) about CCHF clinical manifestations and complications of CCHF and considerations for planning clinical trials (10 min)  
Questions for clarifications (5 min)                                           | T. Fletcher                               |
|            | Overview of diagnostic tools to advance clinical  
(confirmatory diagnosis, assays for vaccine development) (10 min)  
Questions for clarifications (5 min)                                           | G. Korukluoglu                            |
|            | What critical epidemiological studies do we need to plan before conducting efficacy trials (1 hour 30)  
Questions for clarifications (5 min)                                           | Plenary Discussion, moderated by A. Papa |
| 12:45 –    | Lunch - break                                                       |                                           |
| 13:45 –    | **Part II – CCHF Therapeutics evaluation**  
Systematic review on the use of ribavirin in treating CCHF patients (10 min)  
Questions for clarifications (5 min)                                           | S. Johnson                                |
| 15:15      | Draft TPP and overview of CCHF candidate therapeutics (10 min)  
Questions for clarification (5 min)                                           | S. Bavari                                 |
|            | Considerations for trial design of CCHF therapeutics  
(Phase 2b/Phase 3): target population, randomization, comparator (10 min) | I. Longini                                |
### WHO consultation on clinical trial design

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 – 15:35</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>15:35 – 17:05</td>
<td><strong>Part III – CCHF Vaccine evaluation</strong>&lt;br&gt;Lessons learned from the implementation of a CCHF vaccine in Bulgaria and what an ideal CCHF vaccine would look like (10 min)&lt;br&gt;Questions for clarifications (5 min)&lt;br&gt;Summarizing the evidence from animal models for vaccine development (10 min)&lt;br&gt;Questions for clarifications (5 min)&lt;br&gt;Overview of CCHF vaccine candidates (10 min)&lt;br&gt;Questions for clarifications (5 min)&lt;br&gt;Considerations for trial design of CCHF vaccines (Phase 2b/Phase 3): target population, randomization, comparator (15 min)&lt;br&gt;<strong>Points of Discussion</strong> (30 min)&lt;br&gt;- What clinical endpoints are “best suited” for vaccine trials?&lt;br&gt;- What endpoints are the most informative? The most feasible? What should be the primary endpoint? Secondary/exploratory endpoints?</td>
<td>I. Christova&lt;br&gt;A. Mirazimi&lt;br&gt;R. Hewson&lt;br&gt;I. Longini&lt;br&gt;ALL</td>
</tr>
<tr>
<td>17:05-17:30</td>
<td><strong>Summary of recommendations / next steps</strong>&lt;br&gt;<strong>Adjourn</strong></td>
<td>ALL</td>
</tr>
<tr>
<td>18:00</td>
<td><strong>Cocktail</strong></td>
<td></td>
</tr>
</tbody>
</table>